However, there was no difference in infiltrating regulatory T cells between B16-OVA-USP18 and B16-OVA-GFP subcutaneous tumor (Additional file1: Figure S6C).Next we explored whether delivery of USP18 into the tumor microenvironment enhances CTL activity against subcutaneous B16-OVA tumor. This evidence concerns the gene USP18 and neoplasm.